Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Scientists discover novel mechanism that influences GAS virulence at early steps of necrotizing fasciitis

Scientists discover novel mechanism that influences GAS virulence at early steps of necrotizing fasciitis

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

Research may lead to potential treatment for deadly bacterial infections

Research may lead to potential treatment for deadly bacterial infections

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

Three new spin-offs emerged from Helmholtz Zentrum München

Three new spin-offs emerged from Helmholtz Zentrum München

Research opens way to possible new treatments for bacterial infections

Research opens way to possible new treatments for bacterial infections

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera enhances innate immune responses to Imprime PGG drug candidate

Scientists discover genetic signature mechanism in immune system as driving force for childhood leukaemia

Scientists discover genetic signature mechanism in immune system as driving force for childhood leukaemia

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Antipsychotic medication can actively combat cells of difficult-to-treat form of ALL

Antipsychotic medication can actively combat cells of difficult-to-treat form of ALL

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Notre Dame, Loyola partner to provide direct support for revolutionary new cancer research

Notre Dame, Loyola partner to provide direct support for revolutionary new cancer research

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

Epizyme achieves POC milestone in EPZ-5676 DOT1L inhibitor clinical program

Epizyme achieves POC milestone in EPZ-5676 DOT1L inhibitor clinical program

Study examine effect of high out-of-pocket drug costs for targeted cancer therapies on patients

Study examine effect of high out-of-pocket drug costs for targeted cancer therapies on patients

Protein may be major culprit when breast cancer metastasizes to the brain

Protein may be major culprit when breast cancer metastasizes to the brain

Cord Blood America achieves AABB accreditation for cell therapy activity

Cord Blood America achieves AABB accreditation for cell therapy activity

Hopkins scientists design new mouse that mimics common form of leukemia

Hopkins scientists design new mouse that mimics common form of leukemia

Study suggests that ROR1 could be an important therapeutic target for patients with CLL

Study suggests that ROR1 could be an important therapeutic target for patients with CLL

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.